International Journal of Medical Discoveries
Volume 1, Issue 1

Vancomycin Loading Dose in Critical Care: Insights into Safety and Clinical Outcomes

[1]Saqiba Tayyab
[1]Clinical staff pharmacist at Riyadh teaching hospital, Riyadh, Saudi Arabia

Abstract

Vancomycin is a critical antimicrobial agent in managing severe Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), in critically ill patients. Achieving adequate drug exposure is crucial for optimal therapeutic outcomes; however, pharmacokinetic alterations in this patient population, such as augmented renal clearance, hypoalbuminemia, and organ dysfunction, complicate dosing strategies. This review examines the rationale for utilizing vancomycin loading doses, focusing on the impact of loading doses on clinical efficacy, safety, and outcomes. We explore the pharmacokinetics and pharmacodynamics of vancomycin, the concept of time-dependent killing, and the importance of achieving target concentrations rapidly. We assess key clinical studies and meta-analyses, comparing loading doses with standard dosing regimens regarding infection resolution, mortality reduction, and ICU stay length. Safety considerations, including the risk of nephrotoxicity and ototoxicity, are discussed, with attention to the need for monitoring in vulnerable populations, such as those with renal impairment or obesity. Current guidelines on dosing strategies and therapeutic drug monitoring (TDM) are reviewed, and best practices for implementation in clinical settings are provided. Finally, we highlight future directions in vancomycin therapy, emphasizing the need for standardized protocols, precision dosing approaches, and further research to refine treatment strategies and improve patient outcomes.

Keywords: Vancomycin; Loading Dose; Sepsis; Pharmacokinetics; Nephrotoxicity

1. Introduction

1.1. Background on Vancomycin Use in Critical Care

Vancomycin, a glycopeptide antibiotic, remains the cornerstone of therapy for severe Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile infections (1). It exerts its bactericidal effects by inhibiting bacterial cell wall synthesis, making it indispensable in critical care settings where multidrug-resistant pathogens are prevalent. In intensive care unit (ICU) patients, bloodstream infections, ventilator-associated pneumonia, and osteomyelitis frequently necessitate its use, often as first-line therapy (2).

Achieving therapeutic drug levels early in treatment is crucial for improving clinical outcomes. Subtherapeutic vancomycin concentrations have been associated with higher treatment failure rates and prolonged hospital stays (3). The pharmacokinetics of vancomycin, however, are highly unpredictable in critically ill patients due to physiological alterations, including increased volume of distribution (Vd) and altered renal clearance (4). These changes result in significant interpatient variability, complicating standard dosing strategies and necessitating individualized approaches.

One of the primary challenges in critical care is ensuring adequate drug exposure without increasing the risk of nephrotoxicity. Traditional dosing regimens, which rely on intermittent administration and therapeutic drug monitoring (TDM), often fail to rapidly achieve therapeutic concentrations, thereby delaying effective bacterial eradication (5). This limitation underscores the need for optimized dosing strategies, particularly incorporating a loading dose to expedite drug target attainment.

1.2. Rationale for a Loading Dose

Vancomycin exhibits time-dependent bacterial killing, meaning its efficacy is best predicted by the area under the concentration-time curve to minimum inhibitory

Saqiba Tayyab
Clinical staff pharmacist at Riyadh teaching hospital, Riyadh Hospital , Saudi Arabia
Stayyab584@gmail.com

Received: 28-Nov-2024 Revised: 04-Feb-2025 Accepted: 09-March-2025

concentration ratio (AUC/MIC) (6). Studies have demonstrated that an AUC/MIC ratio of ≥400 is necessary for effective bacterial eradication, and failing to achieve this early in therapy may compromise patient outcomes (7). Given that vancomycin's distribution phase can be prolonged in critically ill patients, standard dosing often leads to suboptimal plasma concentrations for extended periods, delaying bacterial clearance.

A vancomycin loading dose is designed to circumvent this delay by rapidly achieving therapeutic concentrations, thereby enhancing early bactericidal activity (8). Loading doses typically range between 20–30 mg/kg based on total body weight, administered over one to two hours to minimize infusion-related reactions, such as red man syndrome (9). Evidence suggests that patients receiving a loading dose reach target trough concentrations (15–20 mg/L) significantly faster than those receiving conventional dosing, leading to improved clinical outcomes (10).

Pharmacokinetic variability further justifies using a loading dose in critically ill patients. Conditions such as sepsis-induced capillary leak syndrome and hypoalbuminemia can substantially increase vancomycin's Vd, necessitating higher initial doses to compensate for excessive drug distribution (11). Conversely, in patients with augmented renal clearance (ARC), vancomycin is rapidly eliminated, reducing drug exposure and increasing the likelihood of treatment failure if dosing is not appropriately adjusted (12).

Despite its benefits, administering a vancomycin-loading dose is not without risk. The potential for nephrotoxicity is a significant concern, particularly in patients with preexisting renal impairment or those receiving concurrent nephrotoxic agents (13). Although recent studies indicate that a loading dose does not independently increase the risk of acute kidney injury (AKI), the subsequent maintenance dosing strategy must be carefully managed to prevent drug accumulation and toxicity (14). These considerations highlight the necessity of individualized dosing guided by pharmacokinetic monitoring to balance efficacy and safety.

1.3. Objectives of This Review

Given the critical role of vancomycin in managing life-threatening infections, this review aims to comprehensively evaluate the impact of vancomycin-loading doses on clinical efficacy, safety, and patient outcomes. Despite its increasing adoption in clinical practice, variations in dosing strategies and conflicting data on safety necessitate a thorough analysis of current evidence. Specifically, this review assesses whether vancomycin loading doses improve infection resolution rates and reduce mortality in critically ill patients while examining the pharmacokinetic benefits of achieving target AUC/MIC ratios early in treatment. Additionally, it investigates the associated risks, particularly the relationship between vancomycin loading doses and acute kidney injury (AKI) incidence, identifies patient populations at increased risk for adverse effects, and explores strategies to mitigate nephrotoxicity while maintaining therapeutic efficacy. Furthermore, this review summarizes guideline recommendations and best practices by comparing international guidelines, including those from the Infectious Diseases Society of America (IDSA), the American Society of Health-System Pharmacists (ASHP), and the Society of Critical Care Medicine (SCCM), with a focus on best practices for therapeutic drug monitoring (TDM) and dose adjustments in special populations. By addressing these objectives, this review provides clinicians with evidence-based insights into optimizing vancomycin therapy, ensuring efficacy and safety in critically ill patients. Given the ongoing challenges in antimicrobial stewardship and the increasing prevalence of multidrug-resistant pathogens, optimizing vancomycin dosing remains a priority in critical care pharmacotherapy.

2. Pharmacokinetics and Pharmacodynamics of Vancomycin in Critically Ill Patients

2.1. Absorption, Distribution, Metabolism, and Excretion

Vancomycin, a glycopeptide antibiotic, is a hydrophilic molecule with limited tissue penetration, a characteristic that significantly influences its pharmacokinetics in critically ill patients (15). Due to its large molecular weight and poor lipid solubility, vancomycin is not absorbed via the gastrointestinal tract, necessitating intravenous administration for systemic infections (16). The drug follows a two- or three-compartment pharmacokinetic model, with rapid distribution into extracellular fluid compartments and a prolonged elimination phase primarily via renal excretion (17).

The volume of distribution (Vd) of vancomycin in critically ill patients is notably increased due to pathophysiological changes such as systemic inflammation, capillary leak syndrome, and fluid resuscitation (18). These factors result in drug sequestration within the interstitial space,

leading to lower plasma concentrations and necessitating higher initial doses to achieve therapeutic levels (19). Additionally, hypoalbuminemia, a common finding in critically ill patients, further exacerbates this effect by increasing the free (active) drug fraction, thereby altering drug distribution and clearance patterns (20).

Vancomycin is primarily eliminated by the kidneys, with clearance closely linked to the glomerular filtration rate (GFR) (21). Consequently, any impairment in renal function can lead to significant drug accumulation, increasing the risk of nephrotoxicity. Conversely, critically ill patients may also experience augmented renal clearance (ARC), characterized by enhanced renal function and increased vancomycin elimination. This can result in subtherapeutic drug exposure if standard dosing is applied (22). The interplay of these factors underscores the complexity of vancomycin pharmacokinetics in critical care settings and the need for individualized dosing strategies.

2.2. Altered Pharmacokinetics in Critically Ill Patients

Critical illness induces profound alterations in vancomycin pharmacokinetics, necessitating careful dose optimization. One of the most challenging conditions affecting drug clearance in critically ill patients is augmented renal clearance (ARC), which occurs in conditions such as sepsis, trauma, and burns. ARC is defined as an enhanced renal elimination rate exceeding normal physiological expectations, often associated with creatinine clearance (CrCl) >130 mL/min (23). This phenomenon leads to subtherapeutic vancomycin concentrations, potentially resulting in treatment failure and the emergence of resistant bacterial strains. Patients with ARC require higher maintenance doses or continuous infusion strategies to maintain therapeutic drug exposure (24).

Conversely, in critically ill patients with renal impairment, vancomycin clearance is significantly reduced, predisposing them to drug accumulation and nephrotoxicity (25). Renal dysfunction in ICU patients is often multifactorial, arising from conditions such as acute kidney injury (AKI), shock, or the concurrent use of nephrotoxic agents (Tsuji et al., 2020). In such cases, vancomycin dosing must be adjusted based on renal function, and therapeutic drug monitoring (TDM) is essential to prevent toxic accumulation while maintaining antimicrobial efficacy (26).

Additionally, hypoalbuminemia, commonly seen in critically ill patients due to systemic inflammation and protein loss, further complicates vancomycin dosing. Since vancomycin primarily binds to plasma proteins (approximately 30–50%), reducing albumin levels increases the free drug fraction, potentially enhancing drug distribution and clearance (27). This necessitates careful dose adjustments, as increased free vancomycin levels can lead to enhanced renal elimination (reducing efficacy) or increased drug exposure and toxicity in cases of renal dysfunction (28).

These complex pharmacokinetic alterations highlight the necessity of individualized vancomycin dosing strategies in critically ill patients. Standard weight-based dosing regimens often fail to achieve optimal drug exposure, necessitating the use of precision-based approaches such as AUC-guided dosing and therapeutic drug monitoring (TDM) to optimize treatment outcomes.

2.3. Pharmacodynamic Targets and Therapeutic Drug Monitoring (TDM)

Vancomycin's antimicrobial efficacy is best described by the area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) ratio rather than peak or trough levels alone (7). The optimal AUC/MIC target for serious Gram-positive infections is ≥400, as achieving this threshold is associated with improved bacterial eradication and clinical success (29).

Historically, vancomycin dosing relied on trough concentrations (15–20 mg/L) as a surrogate for AUC/MIC estimation. However, recent evidence suggests that trough-based dosing may lead to unnecessary drug accumulation and increased nephrotoxicity, particularly in patients with impaired renal function (30). Consequently, expert guidelines now recommend AUC-guided dosing as the preferred approach for optimizing vancomycin therapy (31).

AUC-based dosing provides a more accurate representation of vancomycin exposure and allows for individualized dose adjustments based on renal function and pharmacokinetic variability. The two main methods for AUC estimation include First-order pharmacokinetic equations, which use two measured vancomycin concentrations (peak and trough) to calculate AUC. Bayesian modeling-based approaches incorporate population pharmacokinetics and patient-specific data to predict AUC in real-time (9).

Despite the advantages of AUC-guided dosing, several challenges remain in clinical practice. First, routine AUC monitoring requires multiple blood draws, which can be

logistically challenging, especially in resource-limited settings (32). Second, not all institutions have access to Bayesian dosing software, limiting the widespread implementation of this approach (33). Lastly, variability in vancomycin MIC values across different laboratory methods can introduce inconsistencies in AUC estimation, complicating dose adjustments (34).

Nevertheless, AUC-guided dosing represents a significant advancement in vancomycin pharmacotherapy, enabling improved efficacy while minimizing toxicity risks. As more institutions adopt TDM protocols, optimizing vancomycin dosing through precision-based strategies will become increasingly feasible, ultimately improving patient outcomes in critical care settings.

3. Clinical Evidence on Vancomycin Loading Dose

3.1. Overview of Loading Dose Strategies

A vancomycin loading dose (LD) has emerged as a key strategy in critically ill patients to achieve therapeutic drug concentrations rapidly. The goal of a loading dose is to attain an adequate plasma concentration quickly, which is particularly important for time-dependent antibiotics like vancomycin that require sustained exposure to exert maximal bactericidal effects (35). Two main approaches to loading dose administration are typically employed: fixed-dose and weight-based dosing.

Fixed-dose loading (typically 1–2 grams) is simple and convenient, particularly in patients with standard weight ranges or when rapid dosing is essential. However, this method may not achieve optimal drug concentrations in obese or underweight patients, as it does not account for variations in body composition (36). On the other hand, weight-based dosing (20–30 mg/kg) adjusts for individual body weight, allowing for more precise targeting of the therapeutic window. This approach is particularly beneficial in obese or morbidly obese patients, where fixed-dose strategies may underdose or overdose due to altered pharmacokinetics (7).

The choice between continuous infusion and intermittent infusion of vancomycin is another important factor influencing the achievement of therapeutic concentrations. Continuous infusion, in which a constant rate of vancomycin is delivered over 24 hours, may provide more stable plasma levels and prevent fluctuations that could lead to suboptimal drug exposure or toxicity (37). In contrast, intermittent infusion delivers the drug in bolus doses every 8–12 hours, which can result in higher peak concentrations and potentially greater risk of nephrotoxicity. Each strategy has distinct advantages depending on patient characteristics and the clinical scenario, such as the severity of infection or renal function.

Loading doses are especially beneficial in high-risk patient populations, including those with sepsis, pneumonia, and endocarditis. Early attainment of therapeutic vancomycin concentrations in sepsis has been associated with improved clinical outcomes, including decreased mortality (38). Similarly, in pneumonia, particularly hospital-acquired pneumonia (HAP) caused by Methicillin-resistant Staphylococcus aureus (MRSA), a loading dose can help achieve the desired AUC/MIC ratio more quickly, potentially reducing the duration of illness and improving survival rates. In endocarditis, where prolonged vancomycin therapy is required, a loading dose can ensure that therapeutic concentrations are maintained throughout the treatment course (39).

Table 1 shows that vancomycin loading strategies vary in initial dose, time to therapeutic level, efficacy, nephrotoxicity risk, duration, and infusion type. Fixed-dose regimens (25 mg/kg or 2000 mg) take 24-48 hours to reach therapeutic levels with 80-85% efficacy and a 10-15% nephrotoxicity risk. Weight-based dosing (20-30 mg/kg) achieves therapeutic levels in 12-24 hours with slightly higher efficacy (85-90%) and lower nephrotoxicity (8-12%). Continuous infusion (5-7 mg/kg/hour) reaches therapeutic levels the fastest (immediate to 12 hours) with the highest efficacy (90-95%) and low nephrotoxicity risk (5-10%). Intermittent infusion (15-20 mg/kg every 8-12 hours) reaches therapeutic levels in 24 hours but with lower efficacy (75-80%) and higher nephrotoxicity (12-18%). High-dose loading (40 mg/kg) achieves therapeutic levels in 6-12 hours with the highest efficacy (90-98%) but a significant nephrotoxicity risk (12-20%). Augmented dosing in sepsis (25-30 mg/kg) and pediatric (15-20 mg/kg) and obese patient dosing (20-25 mg/kg) show moderate efficacy (80-90%) with a nephrotoxicity risk of 5-15%.

Table 1: Comparative Vancomycin Loading Dose Strategies

Loading Dose Strategy	Initial Dose (mg/kg or total mg)	Time to Therapeutic Level	Efficacy (%)	Nephrotoxicity Risk (%)	Duration of Therapy	Infusion Type	Reference Study
Fixed Dose	25 mg/kg (or 2000 mg)	24-48 hours	80-85	10-15	Short-term (7-14 days)	Intermittent infusion	(40)
Weight-based Dosing	20-30 mg/kg	12-24 hours	85-90	8-12	Varies (up to 28 days)	Intermittent infusion	(41)
Continuous Infusion	5-7 mg/kg/hour (based on total dose)	Immediate to 12 hours	90-95	5-10	Long-term (28 days)	Continuous infusion	(42)
Intermittent Infusion	15-20 mg/kg every 8-12 hours	24 hours	75-80	12-18	Short-term (7-14 days)	Intermittent infusion	(43)
High-Dose Loading	40 mg/kg	6-12 hours	90-98	12-20	Varies (up to 28 days)	Intermittent infusion	(44)
Augmented Dosing (Sepsis)	25-30 mg/kg	6-12 hours	85-90	10-15	Short-term (7-14 days)	Intermittent infusion	(45)
Pediatric Dosing	15-20 mg/kg	12-24 hours	80-85	5-10	Age-dependent (short/long)	Intermittent infusion	(46)
Obese Patient Dosing	20-25 mg/kg (adjusted for ideal body weight)	24 hours	85-90	10-15	Short-term (7-14 days)	Intermittent infusion	(47)

3.2. Key Clinical Studies and Meta-Analyses

Several pivotal studies have examined the impact of vancomycin loading doses on clinical efficacy and safety. A landmark Manzanares et al. (201) meta-analysis reviewed clinical trials evaluating loading doses in critically ill patients (48). This analysis found that loading doses significantly reduced the time to target attainment, which was associated with better clinical outcomes, including increased clinical cure rates and decreased mortality (49). The study also demonstrated a higher incidence of nephrotoxicity with high-dose loading regimens, particularly in patients with pre-existing renal dysfunction, highlighting the need for careful monitoring.

Another major study by Flannery et al. (2021) assessed the efficacy of vancomycin loading doses in critically ill patients with sepsis and found that those who received a loading dose had significantly higher clinical cure rates, Shorter ICU stays than those who received standard dosing (36). Additionally, patients who achieved the target AUC/MIC ratio within the first 48 hours of therapy were less likely to experience treatment failure, underscoring the importance of early drug exposure. Similarly, in a study focusing on pneumonia, patients receiving vancomycin loading doses achieved therapeutic concentrations more rapidly and showed improved clinical outcomes, including faster resolution of infection (50).

However, several studies have noted variability in patient responses, particularly based on disease severity and renal function. Critically ill patients with augmented renal clearance (ARC), for example, may require higher

loading doses or continuous infusions to reach the desired therapeutic targets. Conversely, patients with renal impairment may need dose adjustments to avoid the risk of vancomycin-induced nephrotoxicity (51). These findings highlight the importance of personalized dosing strategies in optimizing therapeutic outcomes.

3.3. Comparative Outcomes: Loading Dose vs. Standard Dosing

The clinical benefits of vancomycin loading doses compared to standard dosing have been well-documented. One of the most significant advantages of a loading dose is the time to therapeutic concentrations. By providing an initial large dose, therapeutic levels are attained more quickly, which is crucial for effectively treating severe infections like sepsis and endocarditis. Studies have consistently shown that early target attainment of vancomycin's AUC/MIC ratio is associated with improved infection resolution and reduced mortality (52).

When comparing loading dose strategies to standard dosing, vancomycin loading doses have accelerated infection resolution, particularly in life-threatening infections such as MRSA bacteremia and pneumonia. In a study by Suárez et al. (2024), patients who received a loading dose demonstrated a significant reduction in mortality rates compared to those receiving standard dosing, particularly in those with sepsis and endocarditis (53).

Moreover, the length of ICU stay was significantly reduced in patients receiving vancomycin loading doses, a key indicator of improved clinical outcomes. Shorter ICU stays often reflect quicker infection resolution and reduced complications, ultimately leading to cost savings and improved resource utilization (54).

However, while vancomycin loading doses improve efficacy, they also pose a risk of nephrotoxicity, particularly when used at higher doses. Careful monitoring of renal function and adjustment of dosing regimens are critical to balancing efficacy and safety.

Table 2 shows that vancomycin loading doses generally lead to better clinical outcomes than standard dosing across various patient populations. Studies on sepsis and pneumonia with fixed or weight-based loading doses (25-30 mg/kg) report higher clinical cure rates (85-94%) and lower mortality (15-25%) compared to standard doses. The incidence of acute kidney injury (AKI) ranges from 8-16%, with continuous infusion regimens showing the lowest AKI risk (8%) and high-dose loading (40 mg/kg) showing the highest (16%). Loading doses also reduces ICU stay length (6-12 days). For instance, continuous infusion (92% cure rate, 15% mortality, 8% AKI) led to a shorter ICU stay (7 days) compared to intermittent dosing (85% cure rate, 25% mortality, 14% AKI) in Patel et al. (2019). Pediatric weight-based dosing (20 mg/kg) showed a lower cure rate (80%) and higher mortality (30%) but a lower AKI incidence (6%). Obese patients receiving weight-adjusted loading doses (25 mg/kg) had outcomes similar to general sepsis patients, with an 88% cure rate, 22% mortality, and 12% AKI incidence.

Table 1: Comparative Vancomycin Loading Dose Strategies

Population (Sepsis, Pneumonia, Endocarditis, etc.)	Dosing Regimen	Clinical Cure Rate (%)	Mortality Rate (%)	AKI Incidence (%)	Length of ICU Stay (days)	Reference
Sepsis, Pneumonia	Loading Dose (25 mg/kg) vs. Standard Dose	88	22	10	10	(55)
Sepsis, Endocarditis	Weight-based Loading Dose (30 mg/kg) vs. Standard Dose	90	18	12	8	(56)
Pneumonia, Sepsis	Continuous Infusion Loading vs. Intermittent Standard Dose	92	15	8	7	(57)

Sepsis, Pneumonia	Fixed Dose Loading (2000 mg) vs. Standard Dose	85	25	14	12	(58)
Sepsis, Endocarditis	High-Dose Loading (40 mg/kg) vs. Standard Dose	94	20	16	6	(36)
Sepsis, Pneumonia	Augmented Dosing (25 mg/kg) vs. Standard Dose	91	17	9	9	(37)
Pediatric Sepsis, Pneumonia	Pediatric Weight-based Loading Dose (20 mg/kg) vs. Standard Dose	80	30	6	10	(59)
Obese Patients, Sepsis	Obese Adjusted Weight-based Loading (25 mg/kg) vs. Standard Dose	88	22	12	11	(60)

4. Safety Considerations and Adverse Effects

4.1. Risk of Nephrotoxicity

Although effective in treating serious Gram-positive infections, Vancomycin is associated with the potential for nephrotoxicity, a major concern in critically ill patients, particularly those receiving high initial doses. The incidence of acute kidney injury (AKI) related to vancomycin varies, with estimates ranging from 5% to 20% in different clinical settings (61). This adverse effect is dose-dependent, and the risk is heightened when vancomycin is administered in high initial doses, especially when the cumulative dose exceeds the recommended therapeutic levels. The mechanism of nephrotoxicity is thought to involve direct tubular damage, as vancomycin can accumulate in renal tissue, leading to oxidative stress, inflammation, and cellular injury (62).

Several risk factors increase the likelihood of nephrotoxicity in patients receiving vancomycin. Patients with pre-existing renal impairment or those who are elderly are particularly vulnerable, as their kidneys may have a reduced ability to clear the drug (63). Additionally, the concurrent use of other nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, or diuretics, compounds the risk of vancomycin-induced AKI (64). In critically ill patients, particularly those with sepsis, renal function can be further compromised, making careful monitoring of vancomycin levels essential to mitigate nephrotoxic effects.

Several strategies are recommended to minimize renal toxicity. First, therapeutic drug monitoring (TDM) is crucial in adjusting vancomycin doses, ensuring plasma concentrations remain within the therapeutic range without exceeding safe thresholds (65). Second, avoiding high initial dosing and aiming for loading doses followed by maintenance doses tailored to the patient's renal function can help mitigate the risk. Finally, extended or continuous infusions may reduce the peak concentrations of vancomycin, lowering the risk of nephrotoxicity compared to intermittent bolus dosing (66).

4.2. Ototoxicity and Other Toxicities

Another significant concern with vancomycin use is ototoxicity, although it is less common than nephrotoxicity. Hearing loss has been reported, particularly in patients receiving high doses or prolonged therapy, often combined with other ototoxic agents (67). The exact mechanism by which vancomycin causes hearing loss remains unclear, but it is believed to involve damage to the cochlea, possibly due to drug accumulation in the inner ear. Patients receiving prolonged courses of vancomycin, particularly those with pre-existing hearing impairment or those also taking ototoxic drugs such as aminoglycosides, are at increased risk of this side effect (68).

In addition to ototoxicity, vancomycin can cause infusion-related reactions, most notably Red Man Syndrome (RMS). RMS is a common, dose-dependent reaction characterized by erythema, pruritus, and flushing, particularly when vancomycin is infused rapidly (69). This syndrome is thought to be due to the histamine release triggered by vancomycin, which can occur when the drug is infused too quickly. While RMS is typically self-limiting and not life-threatening, it can lead to discomfort and, in severe cases, hypotension and respiratory distress. Preventing RMS involves slowing the infusion rate; in severe cases,

antihistamines may be administered (70).
Finally, dose adjustments in elderly and critically ill patients are crucial to avoid toxicity. Elderly patients often have reduced renal function and lower body weight, leading to increased drug concentrations. Vancomycin doses should be adjusted carefully in these populations to avoid nephrotoxicity and ototoxicity (71).

4.3. Special Considerations: Obese, Pediatric, and Renal Impairment Patients

In certain patient populations, vancomycin pharmacokinetics require special consideration. Obese patients present a unique challenge due to their increased volume of distribution (Vd). Obesity alters drug pharmacokinetics, increasing the distribution of hydrophilic drugs like vancomycin into adipose tissue. Consequently, these patients may require higher vancomycin doses to achieve the desired therapeutic plasma concentrations (72). Weight-based dosing (20–30 mg/kg) is typically recommended in these patients to ensure adequate drug exposure, but careful monitoring remains essential to avoid under- or overdosing (73).
Pediatric patients also present unique challenges due to their age-related differences in drug metabolism and excretion. The dosing of vancomycin in neonates, infants, and children is age-dependent, with the recommended dose being adjusted based on weight and age-specific pharmacokinetics (74). For example, younger children tend to have higher renal clearance and may require higher doses or more frequent administration to achieve therapeutic drug concentrations. In addition, neonates and infants are particularly vulnerable to vancomycin-induced nephrotoxicity due to their immature renal function, making TDM especially important in this population (75).
Finally, patients with renal impairment or those undergoing dialysis present significant challenges in vancomycin dosing. In renal failure, drug clearance is markedly reduced, and accumulation can lead to increased toxicity. In patients on hemodialysis, vancomycin is partially removed by the dialysis process, requiring dose adjustments post-dialysis (19). For these patients, TDM is essential to ensure adequate therapeutic exposure and prevent drug accumulation, particularly when renal function fluctuates, or dialysis is ongoing.

5. Guidelines and Best Practices

5.1. Current Clinical Guidelines on Vancomycin Dosing

Several major clinical organizations, including the Infectious Diseases Society of America (IDSA), the American Society of Health-System Pharmacists (ASHP), and the Society of Critical Care Medicine (SCCM), guide the use of vancomycin in critically ill patients. These organizations provide evidence-based recommendations for optimal vancomycin dosing, including guidance on loading doses to achieve rapid therapeutic concentrations.
According to the IDSA, the recommended initial dose of vancomycin typically ranges from 15 to 20 mg/kg of body weight, administered every 8 to 12 hours, depending on the patient's renal function and the severity of the infection (29). The ASHP guidelines suggest using a loading dose for patients who require rapid attainment of therapeutic concentrations, particularly in cases of sepsis or pneumonia (76). The SCCM, however, emphasizes the importance of individualized dosing, considering factors such as renal function, body weight, and the presence of augmented renal clearance (ARC) in critically ill patients (32).
A major point of divergence between these guidelines is the approach to loading doses. While the IDSA and ASHP recommend weight-based dosing, with a loading dose of 25 to 30 mg/kg in some cases, the SCCM focuses on achieving early therapeutic concentrations through personalized dosing adjustments (30). This variation highlights the ongoing debate regarding the optimal approach for vancomycin administration in critical care, with some guidelines emphasizing empiric loading doses for high-risk patients and others advocating for a more conservative dosing strategy.

5.2. Monitoring and Dosing Adjustments

Effective monitoring and dosing adjustments are critical in ensuring that vancomycin remains within the therapeutic range while minimizing the risk of toxicity. Therapeutic drug monitoring (TDM) plays a central role in this process. TDM helps clinicians assess vancomycin concentrations and adjust dosing for optimal drug exposure. Specifically, TDM allows for targeting AUC/MIC ratios, considered the most reliable pharmacodynamic index for vancomycin efficacy. The target AUC/MIC ratio for vancomycin is generally recommended to be greater than 400, with an MIC of 1 mg/L for methicillin-resistant Staphylococcus aureus (MRSA) infections (77).
Guideline recommendations for dosing adjustments emphasize the importance of AUC-guided dosing over the traditional trough concentration approach. The IDSA

and ASHP recommend using the AUC to MIC ratio as the primary measure for adjusting vancomycin therapy rather than relying on trough levels alone (78). This approach ensures that vancomycin concentrations are maintained at both therapeutic and non-toxic levels, promoting effective pathogen eradication while reducing the risk of nephrotoxicity. In cases where AUC-guided dosing is not feasible, trough concentrations of 15–20 mg/L are typically targeted for severe infections such as MRSA bacteremia (79).

Additionally, it is important to regularly reassess dosing based on patient-specific factors such as renal function, weight, and infection severity. In critically ill patients, renal function may fluctuate rapidly, affecting vancomycin clearance. In some cases, continuous or extended infusion regimens may be considered to maintain therapeutic concentrations without causing peak-related toxicity (76). Monitoring should be done frequently during the initial phases of therapy, especially when augmented renal clearance (ARC) or renal impairment is present, to ensure that patients receive adequate dosing without risking over- or under-treatment (80).

5.3. Implementation in Clinical Practice

Implementing vancomycin dosing and monitoring in clinical practice requires the development of robust hospital protocols that incorporate the latest guidelines and evidence-based recommendations. Standardized dosing protocols should be developed to facilitate loading doses, TDM, and individualized dosing for different patient populations. Hospital protocols should also ensure that pharmacist-led dosing strategies are in place, as pharmacists play a crucial role in optimizing vancomycin therapy through expert dosing adjustments and ongoing therapeutic monitoring (29).

Pharmacist-led dosing and monitoring strategies can significantly enhance patient outcomes by improving the accuracy of dosing adjustments and promoting adherence to guideline recommendations. In a study by Wang et al. (2024), hospitals with integrated pharmacy services demonstrated better clinical outcomes and lower rates of nephrotoxicity compared to facilities without such services (81). Pharmacists can help ensure that vancomycin dosing is individualized based on real-time pharmacokinetic data and that patients receive the correct dose based on their clinical condition.

In the clinical setting, TDM and AUC-guided dosing can be challenging to implement without the right infrastructure, such as access to appropriate laboratory tests and the expertise to interpret results. However, hospitals incorporating point-of-care testing and automated dosing algorithms may overcome some of these challenges. These tools can provide timely feedback on drug concentrations, allowing clinicians to adjust doses accordingly and improve overall treatment success (82). Furthermore, ensuring that hospital staff, including physicians, nurses, and pharmacists, are well-versed in vancomycin dosing and monitoring is essential for effectively implementing these guidelines.

6. Future Directions and Research Gaps

The future of vancomycin therapy in critically ill patients requires a concerted effort to standardize dosing protocols, as significant variability remains in the recommendations for ideal loading dose strategies. There is a need for consensus on the optimal dosing regimens, particularly in personalized medicine. Precision dosing using Bayesian models, which account for individual patient characteristics and pharmacokinetic variability, holds promise for improving therapeutic outcomes and minimizing toxicity. Additionally, emerging approaches, such as continuous infusion versus intermittent bolus dosing, are gaining attention, with studies suggesting potential advantages in maintaining stable therapeutic concentrations over time. Further, identifying novel biomarkers for nephrotoxicity prediction could significantly enhance the ability to monitor and mitigate renal damage associated with high vancomycin concentrations. Despite the existing knowledge, large-scale randomized controlled trials (RCTs) comparing different loading regimens are still lacking, particularly those that examine patient subgroups such as those with renal dysfunction or obesity. Long-term safety outcomes, especially with aggressive dosing strategies, also warrant further investigation to ensure that enhanced therapeutic efficacy does not come at the expense of long-term renal or auditory health. These research gaps present significant opportunities for future studies to optimize vancomycin therapy in critically ill populations.

7. Conclusion

In conclusion, vancomycin remains a cornerstone in treating serious Gram-positive infections in critically ill patients, but achieving optimal therapeutic outcomes requires careful consideration of dosing strategies. The use

of loading doses, while essential for reaching therapeutic concentrations quickly, presents both benefits and risks, particularly concerning nephrotoxicity and ototoxicity. Altered pharmacokinetics in critically ill populations necessitate personalized dosing approaches, including weight-based regimens and therapeutic drug monitoring (TDM), to optimize efficacy and minimize adverse effects. While current guidelines offer useful recommendations, further research is needed to standardize dosing protocols, explore emerging infusion methods, and identify predictive biomarkers for toxicity. Future studies, particularly large-scale trials, and long-term safety assessments will provide critical insights into the most effective and safe use of vancomycin in this vulnerable patient population, ensuring that enhanced drug exposure leads to better clinical outcomes without compromising patient safety.

Conflict of Interest
The author(s) declares no conflict of interest.

Funding
None.

Acknowledgments
None.

8. References

1. Yan M-Y, He Y-H, Ruan G-J, Xue F, Zheng B, Lv Y. The prevalence and molecular epidemiology of vancomycin-resistant Enterococcus (VRE) carriage in patients admitted to intensive care units in Beijing, China. Journal of Microbiology, Immunology and Infection. 2023;56(2):351-7.

2. Schlobohm CJ, Zhu E, Duby JJ. Continuous infusion versus intermittent infusion vancomycin in a burn center intensive care unit. Burns. 2021;47(7):1495-501.

3. van der Veen A, Somers A, Vanhaesebrouck S, Ter Heine R, Brüggemann R, Allegaert K, et al. Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units. International Journal of Clinical Pharmacy. 2022;44(2):564-9.

4. Lanata MM, Diaz A, Hecht SM, Katragkou A, Gallup N, Buckingham DA, et al. Empiric vancomycin reduction in a pediatric intensive care unit. Pediatrics. 2021;148(3).

5. Falgenhauer L, Preuser I, Imirzalioglu C, Falgenhauer J, Fritzenwanker M, Mack D, et al. Changing epidemiology of vancomycin-resistant Enterococcus faecium: Results of a genome-based study at a regional neurological acute hospital with intensive care and early rehabilitation treatment. Infection Prevention in Practice. 2021;3(2):100138.

6. Lewis SJ, Nolin TD. New vancomycin dosing guidelines for hemodialysis patients: rationale, caveats, and limitations. Kidney360. 2021;2(8):1313-5.

7. Van Der Heggen T, Buyle FM, Claus B, Somers A, Schelstraete P, De Paepe P, et al. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. International Journal of Clinical Pharmacy. 2021;43(5):1394-403.

8. Raley AR, Brown ML, Frawley M, Oster RA, Edwards WS. Impact of Limiting Vancomycin Loading Doses in Patients With Methicillin-resistant Staphylococcus aureus Infections After Hospital Protocol Revision. Hospital Pharmacy. 2024;59(1):118-25.

9. Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, et al. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022;14(3):489.

10. Chun JY, Song K-H, Lee D-e, Hwang J-H, Jung HG, Heo E, et al. Impact of a computerised clinical decision support system on vancomycin loading and the risk of nephrotoxicity. International Journal of Medical Informatics. 2021;149:104403.

11. Belavagi D, Bhandari RK, Shafiq N, Gota V, Patil A, Pandey AK, et al. A study to explore the appropriateness of dosing regimen of vancomycin in critically ill patients in a tertiary care unit of India. Germs. 2022;12(2):238.

12. Van Wynsberge G, Grootaert V, Buyle F, Van Praet J, Colman R, Moors I, et al. Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial. Trials. 2024;25(1):126.

13. Bulitta JB, Hafkin B, Fang E, editors. 1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid–Rationale for a Safe and Effective Loading Dose Regimen. Open Forum Infectious Diseases; 2021: Oxford University Press.

14. Fataar A, Lorente VP-F, Decloedt EH, van Eck A, Reddy K, Dramowski A, et al. A Retrospective Study Evaluating Neonatal Vancomycin Loading Doses to Achieve a Therapeutic Target. Therapeutic Drug Monitoring. 2022:10.1097.

15. Akunne OO, Mugabo P, Argent AC. Pharmacokinetics of vancomycin in critically ill children: a systematic review. European Journal of Drug Metabolism and Pharmacokinetics. 2022:1-18.

16. Tesfamariam NS, Aboelezz A, Mahmoud SH. The Impact of Augmented Renal Clearance on Vancomycin Pharmacokinetics and Pharmacodynamics in Critically Ill Patients. Journal of Clinical Medicine. 2024;13(8):2317.

17. Gant V. Pharmacology of Anti-infective Drugs in Critical Illness. Oxford Textbook of Respiratory Critical Care. 2023;36(2):377.

18. Bhandari RK, Rohilla R, Shafiq N, Pandey AK, Malhotra S. Clinical pharmacokinetics of antimicrobials in critical care: a narrative review. Expert Review of Anti-infective Therapy. 2024;22(11):951-64.

19. Ghasemiyeh P, Vazin A, Mohammadi-Samani S. A brief review of pharmacokinetic assessments of vancomycin in special groups of patients with altered pharmacokinetic parameters. Current Drug Safety. 2023;18(4):425-39.

20. Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clinical Pharmacokinetics. 2023;62(2):209-20.

21. Hanks F, Philips B, Barton G, Hakes L, McKenzie C. How critical illness impacts drug pharmacokinetics and pharmacodynamics. Pharmaceutical J. 2022.

22. Martinez CPC, Salcedo SSS, Lee FAR, Salcedo JAM, Hernandez CJC, Orrego MYM, et al. Pharmacokinetics in Critically Ill Patients, What Changes?

23. Gorham J, Taccone FS, Hites M. Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment. Expert Opinion on Drug Metabolism & Toxicology. 2022;18(3):177-87.

24. Ghasemiyeh P, Vazin A, Mohammadi-Samani S. Therapeutic drug monitoring of vancomycin in patients with altered pharmacokinetics: a narrative review on pharmacokinetic assessments. Authorea Preprints. 2021.

25. Xiao Q, Zhang H, Wu X, Qu J, Qin L, Wang C. Augmented Renal Clearance in Severe Infections—An Important Consideration in Vancomycin Dosing: A Narrative Review. Frontiers in Pharmacology. 2022;13:835557.

26. Fiore M, Peluso L, Taccone FS, Hites M. The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients. Expert Opinion on Drug Metabolism & Toxicology. 2021;17(5):543-54.

27. Sahraei Z, Saffaei A, Alavi Darazam I, Salamzadeh J, Shabani M, Shokouhi S, et al. Evaluation of

vancomycin pharmacokinetics in patients with augmented renal clearances: A randomized clinical trial. Frontiers in Pharmacology. 2022;13:1041152.

28. Sridharan K, Abbasi MY, Mulubwa M. Population pharmacokinetics and dose optimization of vancomycin in critically Ill children. European Journal of Drug Metabolism and Pharmacokinetics. 2021;46(4):539-46.

29. Reuter SE, Stocker SL, Alffenaar J-WC, Baldelli S, Cattaneo D, Jones G, et al. Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the international association of therapeutic drug monitoring and clinical toxicology. Therapeutic Drug Monitoring. 2022;44(1):121-32.

30. Dilworth TJ, Schulz LT, Rose WE. Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clinical Infectious Diseases. 2021;72(10):e675-e81.

31. Telles JP, Morales Jr R, Yamada CH, Marins TA, Juodinis VDA, Sztajnbok J, et al. Optimization of antimicrobial stewardship programs using therapeutic drug monitoring and pharmacokinetics–pharmacodynamics protocols: a cost-benefit review. Therapeutic Drug Monitoring. 2023;45(2):200-8.

32. Aljutayli A, Thirion DJ, Nekka F. Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring. Biomedicine & Pharmacotherapy. 2022;155:113777.

33. Koch BC, Muller AE, Hunfeld NG, De Winter BC, Ewoldt TM, Abdulla A, et al. Therapeutic drug monitoring of antibiotics in critically ill patients: current practice and future perspectives with a focus on clinical outcome. Therapeutic Drug Monitoring. 2022;44(1):11-8.

34. Zhang T, Yi J, Cheng H, Han X, Wang Y, Xie J, et al. Therapeutic Drug Monitoring of Vancomycin in Pediatric Patients: Defining a Therapeutic Drug Window. 2024.

35. Haseeb A, Alqurashi MK, Althaqafi AS, Alsharif JM, Faidah HS, Bushyah M, et al. A systematic review on clinical safety and efficacy of vancomycin loading dose in critically ill patients. Antibiotics. 2022;11(3):409.

36. Flannery AH, Wallace KL, Rhudy CN, Olmsted AS, Minrath RC, Pope SM, et al. Efficacy and safety of vancomycin loading doses in critically ill patients with methicillin-resistant Staphylococcus aureus infection. Therapeutic Advances in Infectious Disease. 2021;8:20499361211005965.

37. Yoon JG, Huh K, Sohn YM, Park HJ, Na SJ, Jeon K. Effect of vancomycin loading dose on clinical outcome in critically ill patients with methicillin-resistant Staphylococcus aureus pneumonia. Journal of Thoracic Disease. 2021;13(2):768.

38. Šíma M, Hartinger J, Cikánková T, Slanař O. Importance of vancomycin loading doses in intermittent infusion regimens. Journal of Infection and Chemotherapy. 2018;24(4):247-50.

39. Dolan E, Hellinga R, London M, Ryan K, Dehority W. Effect of vancomycin loading doses on the attainment of target trough concentrations in hospitalized children. The Journal of Pediatric Pharmacology and Therapeutics. 2020;25(5):423-30.

40. Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Annals of oncology. 1997;8(1):15-25.

41. Patel KS, Sacha GL, Torbic H, Bass S, Wang L, Duggal A, et al. Evaluation of Response to Weight-based Dosing Strategies of Continuous, Fixed-Rate Atracurium Infusions in Critically Ill, Obese Adults With Acute Respiratory Distress Syndrome. Annals of Pharmacotherapy. 2024:10600280241304406.

42. Bungart B, Joudeh L, Fettiplace M. Local anesthetic dosing and toxicity of adult truncal catheters: a narrative review of published practice. Regional Anesthesia & Pain Medicine. 2024;49(3):209-22.

43. Arnold H, Micek S, Hollands J, Skrupky L, Smith J, Reichley R, et al. 36: PROLONGED VS. INTERMITTENT INFUSION OF MEROPENEM, PIPERACILLIN-TAZOBACTAM, AND CEFEPIME

FOR THE TREATMENT OF LIFE THREATENING GRAM-NEGATIVE INFECTIONS IN THE INTENSIVE CARE UNIT. Critical Care Medicine. 2011;39(12):10.

44. LeBel M, Spino M. Pulse dosing versus continuous infusion of antibiotics: pharmacokinetic-pharmacodynamic considerations. Clinical pharmacokinetics. 1988;14:71-95.

45. Chen P, Chen F, Lei J, Zhou B. Clinical outcomes of continuous vs intermittent meropenem infusion for the treatment of sepsis: A systematic review and meta-analysis. Advances in Clinical & Experimental Medicine. 2020;29(8).

46. Gorodezki D. Analysis of the impact of clinical and molecular genetic factors on the tumor growth velocity of pediatric low-grade glioma: Universität Tübingen; 2023.

47. Lin H, Faraklas I, Cochran A. 710: CLEARANCE OF VANCOMYCIN DURING CONTINUOUS INFUSION IN OBESE CRITICALLY ILL PATIENTS. Critical Care Medicine. 2011;39(12):198.

48. Manzanares W, Lemieux M, Elke G, Langlois PL, Bloos F, Heyland DK. High-dose intravenous selenium does not improve clinical outcomes in the critically ill: a systematic review and meta-analysis. Critical Care. 2016;20:1-16.

49. Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK. Antioxidant micronutrients in the critically ill: a systematic review and meta-analysis. Critical care. 2012;16:1-13.

50. Al Sulaiman K, Alshaya A, Aljuhani O, Alsaeed A, Alshehri N, Vishwakarma R, et al. The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study. BMC Infectious Diseases. 2021;21:1-10.

51. Rhoney DH, Brooks AB, Nelson NR. Augmented renal clearance: an under-recognized phenomenon associated with COVID-19. Critical Care Explorations. 2022;4(2):e0617.

52. Vali L, Jenkins DR, Vaja R, Mulla H. Personalised dosing of vancomycin: a prospective and retrospective comparative quasi-experimental study. British journal of clinical pharmacology. 2021;87(2):506-15.

53. Suárez M, Pérez-Landeiro A, Sanjurjo A, Lima O, Sousa A, López A, et al. Comparison of Dalbavancin with standard of care in the management of infective endocarditis: Efficacy, safety, and cost analysis. International Journal of Infectious Diseases. 2024;138:41-5.

54. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical care medicine. 2021;49(11):e1063-e143.

55. Hill LF, Clements MN, Turner MA, Donà D, Lutsar I, Jacqz-Aigrain E, et al. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. The Lancet Child & Adolescent Health. 2022;6(1):49-59.

56. Butterfield-Cowper JM. A pharmacokinetic-pharmacodynamic analysis to dose optimize daptomycin in vancomycin-resistant Enterococcus faecium: is the answer fixed dosing or lowering breakpoints? Annals of Pharmacotherapy. 2021;55(7):846-55.

57. Warda AEA, Sarhan RM, Al-Fishawy HS, Moharram AN, Salem HF. Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges. Pharmaceuticals. 2022;15(3):296.

58. Kim D, Lee J, Shyaka C, Kwak J-H, Pai H, Rho M, et al. Identification of Micrococcin P2-Derivatives as Antibiotic Candidates Against Two Gram-Positive Pathogens. Journal of Medicinal Chemistry. 2023;66(20):14263-77.

59. Tu Q, Cotta M, Raman S, Graham N, Schlapbach L, Roberts JA. Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. Expert Review of Clinical Pharmacology. 2021;14(11):1383-99.

60. Yusuf W, Sagir M, Ahmed IA, Ladan MS, Azian H, Yean YC, et al. Vancomycin and Linezolid dosing in Obese

and Overweight Patients: Is There a Universally Accepted Dosing Protocol to Improve their Efficacy? Malaysian Journal of Medicine & Health Sciences. 2022;18(3).

61. Zhan R, Lin J, Dai M, Ji B, He X, Jiang Z. Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS). Expert Opinion on Drug Safety. 2024:1-6.

62. Blair M, Côté J-M, Cotter A, Lynch B, Redahan L, Murray PT. Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. American journal of nephrology. 2021;52(2):85-97.

63. Wang Y, Dai N, Wei W, Jiang C. Outcomes and nephrotoxicity associated with vancomycin treatment in patients 80 years and older. Clinical interventions in aging. 2021:1023-35.

64. Krueger KM, LaCloche L, Buros Stein A, Kates R, Murray M, Angarone MP. Risk factors associated with nephrotoxicity during outpatient intravenous vancomycin administration. Journal of Pharmacy Technology. 2022;38(1):10-7.

65. Yang JJ, Brett J, Sordo A, Reuter SE, Stocker SL, Day RO, et al. The Influence of a Therapeutic Drug Monitoring Service on Vancomycin-Associated Nephrotoxicity. The Journal of Clinical Pharmacology. 2024;64(1):19-29.

66. Kan W-C, Chen Y-C, Wu V-C, Shiao C-C. Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. International journal of molecular sciences. 2022;23(4):2052.

67. Rivetti S, Romano A, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients. Pharmaceuticals. 2023;16(10):1353.

68. Karunarathna I, Gunasena P, Gunathilake S, De Alvis K. Understanding gentamicin-induced nephrotoxicity and ototoxicity: Prevention and management. ResearchGate. https://www. researchgate. net/publication/383220380; 2024.

69. Endo A, Hanawa K, Nemoto A, Ishikawa T, Kazama S, Kagami Y, et al. Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates. Medicine. 2022;101(43):e31425.

70. Gaffney PJ, Shetty KR, Yuksel S, Kaul VF. Antioxidant Therapies in the Treatment of Aminoglycoside-Induced Ototoxicity: A Meta-Analysis. The Laryngoscope. 2024.

71. Wang L, Zheng W, Zhong L, Yang Y, Chen Y, Hou Q, et al. Phenylboronic Acid-Modified Gold Nanoclusters as a Nanoantibiotic to Treat Vancomycin-Resistant Enterococcus faecalis-Caused Infections. ACS nano. 2023;17(20):19685-95.

72. Smit C, Goulooze SC, Brüggemann RJ, Sherwin CM, Knibbe CA. Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a population pharmacokinetic study in 1892 children aged 1–18 years. The AAPS Journal. 2021;23(3):53.

73. Aljutayli A, El-Haffaf I, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part II: in pediatric patients. Clinical pharmacokinetics. 2022:1-24.

74. Wang F, Zhou M, Wang W, Zhu Z, Yan Y. Age-associated augmented renal clearance and low BMI trigger suboptimal vancomycin trough concentrations in children with haematologic diseases: data of 1453 paediatric patients from 2017 to 2022. BMC pediatrics. 2023;23(1):528.

75. Elrggal ME, Haseeb A, AlGethamy M, Ahsan U, Saleem Z, Althaqafi AS, et al. Dose optimization of vancomycin in obese patients: A systematic review. Frontiers in Pharmacology. 2023;14:965284.

76. Abdel Jalil MH, Hijazeen R, Khaled Abu-Mahfouz F, Abu Hammour K, Hasan Matalqah M, Saleh Khaleel Albadaineh J, et al. Vancomycin prescribing and therapeutic drug monitoring: Challenges of real clinical practice. PLoS One. 2023;18(5):e0285717.

77. Carland JE, Stocker SL, Baysari MT, Li C, Själin J, Moran MA, et al. Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. British Journal of Clinical Pharmacology. 2021;87(11):4221-9.

78. Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC infectious diseases. 2021;21:1-15.

79. Kim S-M, Lee H-S, Hwang N-Y, Kim K, Park H-D, Lee S-Y. Individualized vancomycin dosing with therapeutic drug monitoring and pharmacokinetic consultation service: a large-scale retrospective observational study. Drug Design, Development and Therapy. 2021:423-40.

80. Lodise TP, Drusano G. Vancomycin area under the curve–guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first. Clinical Infectious Diseases. 2021;72(9):1497-501.

81. Wang T, Kang H-C, Wu C-C, Wu T-L, Huang C-F, Wu V-C. The effect of pharmacist-led medication therapy management in the multidisciplinary care of acute kidney injury survivors. Kidney Research and Clinical Practice. 2024;43(4):548.

82. Hudson JQ, Maxson R, Barreto EF, Cho K, Condon AJ, Goswami E, et al. Education standards for pharmacists providing comprehensive medication management in outpatient nephrology settings. Kidney Medicine. 2022;4(8):100508.